Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND With FDA
CRWENewswire Highlights: ACTC, IBM, PWRM
Las Vegas, Nevada 11/19/2009 07:26 PM GMT (TransWorldNews)
Las Vegas (CRWENEWSWIRE) Nov. 19, 2009
Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
Advanced Cell Technology, Inc. (OTCBB:ACTC) filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD).
As many as 10 million people in the United States have photoreceptor degenerative disease. The treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptors needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in SMD and AMD, which in turn leads to loss of vision.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine.
________________________________________
IBM's 10 new software products
IBM (NYSE: IBM) offers 10 new software products to help lower application management costs by optimizing the System z mainframe for more workloads, such as data analytics, collaborative application development, application maintenance and other key business processes.
Given System z's ability to reduce costs through server consolidation, IBM and the industry have aggressively extended the breadth of new workloads for the mainframe via 3,800 z/OS-based and 3,000 Linux-based applications. The unique ability of the mainframe to host many application services on one system has helped System z achieve one of the industry's lowest application costs per user. Minimal application costs are important for companies which rely on multiple applications to run their business.
About IBM
International Business Machines Corporation (IBM) develops and manufactures information technology products and services worldwide.
________________________________________
Power3 Medical Products, Inc. (OTCBB: PWRM) President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.”
About Power3 Medical
Power3 Medical is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.
Sign up to receive FREE alerts from CRWENewswire.com at http://www.crwenewswire.com/?page_id=6123
About CRWENewswire.com
CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.
CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).
We encourage investors to join and receive CRWENewswire.com FREE e-mail news and stock watch alerts at http://www.crwenewswire.com/?page_id=6123 and view our full disclaimer.
info@crwenewswire.com
www.crwenewswire.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
CRWE.OB
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
